Skip to main content
Top
Published in: BMC Infectious Diseases 1/2024

Open Access 01-12-2024 | SARS-CoV-2 | Research

Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study

Authors: Ehsan Kakavandi, Kaveh Sadeghi, Mohammad Shayestehpour, Hossein Mirhendi, Abbas Rahimi Foroushani, Talat Mokhtari-Azad, Nazanin Zahra Shafiei Jandaghi, Jila Yavarian

Published in: BMC Infectious Diseases | Issue 1/2024

Login to get access

Abstract

Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious virus that uses angiotensin converting enzyme 2 (ACE2), a pivotal member of the renin–angiotensin system (RAS), as its cell-entry receptor. Another member of the RAS, angiotensin II (Ang II), is the major biologically active component in this system. There is growing evidence suggesting that serum miRNAs could serve as prognostic biomarkers for SARS-CoV-2 infection and regulate ACE2 expression. Therefore, the aim of this study is to evaluate the changes in the serum levels of sACE2 and Ang II, as well as the expression level of miR-141-3p and miR-421 in SARS-CoV-2 positive and negative subjects.

Methods

In the present study, the serum levels of sACE2 and Ang II were measured in 94 SARS-CoV-2 positive patients and 94 SARS-CoV-2 negative subjects with some symptoms similar to those of SARS-CoV-2 positive patients using the ELISA method. In addition, the expression level of miR-141-3p and miR-421 as ACE2 regulators and biomarkers was evaluated using quantitative real-time PCR (qRT-PCR) method.

Results

The mean serum sACE2 concentration in the SARS-CoV-2-positive group was 3.268 ± 0.410 ng/ml, whereas in the SARS-CoV-2 negative group, it was 3.564 ± 0.437 ng/ml. Additionally, the mean serum Ang II level in the SARS-CoV-2 positive and negative groups were 60.67 ± 6.192 ng/L and 67.97 ± 6.837 ng/L, respectively. However, there was no significant difference in the serum levels of sACE2 (P value: 0.516) and Ang II (P value: 0.134) between the SARS-CoV-2 positive and negative groups. Meanwhile, our findings indicated that the expression levels of miR-141-3p and miR-421 in SARS-CoV-2 positive group were significantly lower and higher than SARS-CoV-2 negative group, respectively (P value < 0.001).

Conclusions

Taken together, the results of this study showed that the serum levels of sACE2 and Ang II in SARS-CoV-2 positive and negative subjects were not significantly different, but the expression levels of miR-141-3p and miR-421 were altered in SARS-CoV-2 positive patients which need more investigation to be used as biomarkers for COVID-19 diagnosis.
Literature
1.
go back to reference Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar J, et al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):106006.PubMedPubMedCentralCrossRef Deslandes A, Berti V, Tandjaoui-Lambotte Y, Alloui C, Carbonnelle E, Zahar J, et al. SARS-CoV-2 was already spreading in France in late December 2019. Int J Antimicrob Agents. 2020;55(6):106006.PubMedPubMedCentralCrossRef
2.
go back to reference Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, et al. Serologic Testing of US blood donations to identify severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive antibodies: December 2019–January 2020. Clin Infect Dis. 2020;72(12):e1004–9.CrossRef Basavaraju SV, Patton ME, Grimm K, Rasheed MAU, Lester S, Mills L, et al. Serologic Testing of US blood donations to identify severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Reactive antibodies: December 2019–January 2020. Clin Infect Dis. 2020;72(12):e1004–9.CrossRef
3.
go back to reference Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (New York, NY). 2022;375(6585):1122-7. Merad M, Blish CA, Sallusto F, Iwasaki A. The immunology and immunopathology of COVID-19. Science (New York, NY). 2022;375(6585):1122-7.
4.
go back to reference Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–93.PubMedPubMedCentralCrossRef Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–93.PubMedPubMedCentralCrossRef
5.
go back to reference Shatizadeh Malekshahi S, Yavarian J, Shafiei-Jandaghi NZ. Usage of peptidases by SARS-CoV-2 and several human coronaviruses as receptors: a mysterious story. Biotechnol Appl Chem. 2022;69(1):124–8. Shatizadeh Malekshahi S, Yavarian J, Shafiei-Jandaghi NZ. Usage of peptidases by SARS-CoV-2 and several human coronaviruses as receptors: a mysterious story. Biotechnol Appl Chem. 2022;69(1):124–8.
6.
go back to reference Wang J, Zhao H, An Y. ACE2 shedding and the role in COVID-19. Front Cell Infect Microbiol. 2022;11:1422.CrossRef Wang J, Zhao H, An Y. ACE2 shedding and the role in COVID-19. Front Cell Infect Microbiol. 2022;11:1422.CrossRef
7.
go back to reference Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Diseases: Official Publication Eur Soc Clin Microbiol. 2021;40(5):905–19.CrossRef Beyerstedt S, Casaro EB, Rangel ÉB. COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection. Eur J Clin Microbiol Infect Diseases: Official Publication Eur Soc Clin Microbiol. 2021;40(5):905–19.CrossRef
8.
go back to reference Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–50.PubMedPubMedCentralCrossRef Shirbhate E, Pandey J, Patel VK, Kamal M, Jawaid T, Gorain B, et al. Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention. Pharmacol Rep. 2021;73(6):1539–50.PubMedPubMedCentralCrossRef
9.
go back to reference Reindl-Schwaighofer R, Hödlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, et al. The systemic renin-angiotensin system in COVID-19. Sci Rep. 2022;12(1):20117.PubMedPubMedCentralCrossRef Reindl-Schwaighofer R, Hödlmoser S, Domenig O, Krenn K, Eskandary F, Krenn S, et al. The systemic renin-angiotensin system in COVID-19. Sci Rep. 2022;12(1):20117.PubMedPubMedCentralCrossRef
10.
go back to reference Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol. 2020;251(3):228–48.PubMedPubMedCentralCrossRef Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Gordijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS‐CoV‐2 and the pathophysiology of coronavirus disease 2019 (COVID‐19). J Pathol. 2020;251(3):228–48.PubMedPubMedCentralCrossRef
11.
go back to reference Imai Y, Kuba K, Penninger JM. The renin–angiotensin system in acute respiratory distress syndrome. Drug Discovery Today: Disease Mech. 2006;3(2):225–9.CrossRef Imai Y, Kuba K, Penninger JM. The renin–angiotensin system in acute respiratory distress syndrome. Drug Discovery Today: Disease Mech. 2006;3(2):225–9.CrossRef
12.
go back to reference Vrigkou E, Tsangaris I, Bonovas S, Tsantes A, Kopterides P. The evolving role of the renin–angiotensin system in ARDS. Crit Care. 2017;21(1):1–2.CrossRef Vrigkou E, Tsangaris I, Bonovas S, Tsantes A, Kopterides P. The evolving role of the renin–angiotensin system in ARDS. Crit Care. 2017;21(1):1–2.CrossRef
13.
14.
go back to reference Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 2005;280(47):39353–62.PubMedCrossRef Warner FJ, Lew RA, Smith AI, Lambert DW, Hooper NM, Turner AJ. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. J Biol Chem. 2005;280(47):39353–62.PubMedCrossRef
15.
go back to reference Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020:317. Samavati L, Uhal BD. ACE2, much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol. 2020:317.
16.
go back to reference Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences. 2009;106(14):5871-6. Belouzard S, Chu VC, Whittaker GR. Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites. Proceedings of the National Academy of Sciences. 2009;106(14):5871-6.
17.
go back to reference Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5(1):3595.PubMedCrossRef Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5(1):3595.PubMedCrossRef
18.
go back to reference Elemam NM, Hasswan H, Aljaibeji H, Sharif-Askari NS, Halwani R, Taneera J et al. Profiling levels of serum microRNAs and Soluble ACE2 in COVID-19 patients. Life (Basel). 2022;12(4). Elemam NM, Hasswan H, Aljaibeji H, Sharif-Askari NS, Halwani R, Taneera J et al. Profiling levels of serum microRNAs and Soluble ACE2 in COVID-19 patients. Life (Basel). 2022;12(4).
19.
go back to reference Nersisyan S, Shkurnikov M, Turchinovich A, Knyazev E, Tonevitsky A. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. PLoS ONE. 2020;15(7):e0235987.PubMedPubMedCentralCrossRef Nersisyan S, Shkurnikov M, Turchinovich A, Knyazev E, Tonevitsky A. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. PLoS ONE. 2020;15(7):e0235987.PubMedPubMedCentralCrossRef
20.
go back to reference Sodagar H, Khadem Ansari MH, Asghari R, Alipour S. Evaluation of serum levels of MicroRNA-200 C and ACE2 gene expression in severe and mild phases of patients with COVID-19. Iran J Allergy Asthma Immunol. 2022;21(3):254–62.PubMed Sodagar H, Khadem Ansari MH, Asghari R, Alipour S. Evaluation of serum levels of MicroRNA-200 C and ACE2 gene expression in severe and mild phases of patients with COVID-19. Iran J Allergy Asthma Immunol. 2022;21(3):254–62.PubMed
21.
go back to reference Mirzavi F, Ebrahimi S, Ghazvini K, Hasanian SM, Hashemy SI. Diagnostic, Prognostic, and therapeutic potencies of circulating miRNAs in Acute myocardial infarction. Crit Rev Eukaryot Gene Expr. 2019;29(4):333–42.PubMedCrossRef Mirzavi F, Ebrahimi S, Ghazvini K, Hasanian SM, Hashemy SI. Diagnostic, Prognostic, and therapeutic potencies of circulating miRNAs in Acute myocardial infarction. Crit Rev Eukaryot Gene Expr. 2019;29(4):333–42.PubMedCrossRef
22.
go back to reference Jankovic M, Nikolic D, Novakovic I, Petrovic B, Lackovic M, Santric-Milicevic M. miRNAs as a potential biomarker in the COVID-19 infection and complications Course, Severity, and Outcome. Diagnostics (Basel). 2023;13(6). Jankovic M, Nikolic D, Novakovic I, Petrovic B, Lackovic M, Santric-Milicevic M. miRNAs as a potential biomarker in the COVID-19 infection and complications Course, Severity, and Outcome. Diagnostics (Basel). 2023;13(6).
23.
go back to reference Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci (Lond). 2014;127(4):243–9.PubMedCrossRef Lambert DW, Lambert LA, Clarke NE, Hooper NM, Porter KE, Turner AJ. Angiotensin-converting enzyme 2 is subject to post-transcriptional regulation by miR-421. Clin Sci (Lond). 2014;127(4):243–9.PubMedCrossRef
24.
go back to reference Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.PubMedCrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.PubMedCrossRef
25.
go back to reference Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020;4(12):1303–12.PubMedCrossRef Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav. 2020;4(12):1303–12.PubMedCrossRef
27.
go back to reference Xavier LL, Neves PFR, Paz LV, Neves LT, Bagatini PB, Timmers LFSM, et al. Does angiotensin II peak in response to SARS-CoV-2? Front Immunol. 2021;11:577875.PubMedPubMedCentralCrossRef Xavier LL, Neves PFR, Paz LV, Neves LT, Bagatini PB, Timmers LFSM, et al. Does angiotensin II peak in response to SARS-CoV-2? Front Immunol. 2021;11:577875.PubMedPubMedCentralCrossRef
28.
go back to reference Babajani F, Kakavand A, Mohammadi H, Sharifi A, Zakeri S, Asadi S, et al. COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. Health Sci Rep. 2021;4(4):e440.PubMedPubMedCentralCrossRef Babajani F, Kakavand A, Mohammadi H, Sharifi A, Zakeri S, Asadi S, et al. COVID-19 and renin angiotensin aldosterone system: Pathogenesis and therapy. Health Sci Rep. 2021;4(4):e440.PubMedPubMedCentralCrossRef
29.
go back to reference Faraji SN, Raee MJ, Hashemi SMA, Daryabor G, Tabrizi R, Dashti FS, et al. Human interaction targets of SARS-CoV-2 spike protein: a systematic review. Eur J Inflamm. 2022;20:1721727X221095382.CrossRef Faraji SN, Raee MJ, Hashemi SMA, Daryabor G, Tabrizi R, Dashti FS, et al. Human interaction targets of SARS-CoV-2 spike protein: a systematic review. Eur J Inflamm. 2022;20:1721727X221095382.CrossRef
30.
go back to reference Elemam NM, Hasswan H, Aljaibeji H, Sharif-Askari NS, Halwani R, Taneera J, et al. Profiling levels of serum microRNAs and soluble ACE2 in COVID-19 patients. Life. 2022;12(4):575.PubMedPubMedCentralCrossRef Elemam NM, Hasswan H, Aljaibeji H, Sharif-Askari NS, Halwani R, Taneera J, et al. Profiling levels of serum microRNAs and soluble ACE2 in COVID-19 patients. Life. 2022;12(4):575.PubMedPubMedCentralCrossRef
31.
go back to reference Rieder M, Wirth L, Pollmeier L, Jeserich M, Goller I, Baldus N, et al. Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am J Hypertens. 2021;34(3):278–81.PubMedCrossRef Rieder M, Wirth L, Pollmeier L, Jeserich M, Goller I, Baldus N, et al. Serum ACE2, angiotensin II, and aldosterone levels are unchanged in patients with COVID-19. Am J Hypertens. 2021;34(3):278–81.PubMedCrossRef
32.
go back to reference Naderi N, Rahimzadeh M. The role of Soluble ACE2 as a prognostic marker in severe COVID-19: a brief Meta-analysis. Endocrine, metabolic & Immune disorders-drug targets (formerly current drug targets-Immune. Endocr Metabolic Disorders). 2023;23(1):70–6. Naderi N, Rahimzadeh M. The role of Soluble ACE2 as a prognostic marker in severe COVID-19: a brief Meta-analysis. Endocrine, metabolic & Immune disorders-drug targets (formerly current drug targets-Immune. Endocr Metabolic Disorders). 2023;23(1):70–6.
33.
go back to reference Bani Hani A, Abu Tarboush N, Ma BA, Alabhoul F, Alansari F, Abuhani A, et al. Serum ACE2 level is Associated with severe SARS-CoV-2 infection: a cross-sectional observational study. Biomark Insights. 2022;17:11772719221125123.PubMedPubMedCentralCrossRef Bani Hani A, Abu Tarboush N, Ma BA, Alabhoul F, Alansari F, Abuhani A, et al. Serum ACE2 level is Associated with severe SARS-CoV-2 infection: a cross-sectional observational study. Biomark Insights. 2022;17:11772719221125123.PubMedPubMedCentralCrossRef
34.
go back to reference Kintscher U, Slagman A, Domenig O, Röhle R, Konietschke F, Poglitsch M, et al. Plasma angiotensin peptide profiling and ACE (angiotensin-converting enzyme)-2 activity in COVID-19 patients treated with pharmacological blockers of the renin-angiotensin system. Hypertension. 2020;76(5):e34–6.PubMedCrossRef Kintscher U, Slagman A, Domenig O, Röhle R, Konietschke F, Poglitsch M, et al. Plasma angiotensin peptide profiling and ACE (angiotensin-converting enzyme)-2 activity in COVID-19 patients treated with pharmacological blockers of the renin-angiotensin system. Hypertension. 2020;76(5):e34–6.PubMedCrossRef
35.
go back to reference Nagy B Jr, Fejes Z, Szentkereszty Z, Sütő R, Várkonyi I, Ajzner É, et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412–4.PubMedCrossRef Nagy B Jr, Fejes Z, Szentkereszty Z, Sütő R, Várkonyi I, Ajzner É, et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412–4.PubMedCrossRef
36.
go back to reference van Lier D, Kox M, Santos K, van der Hoeven H, Pillay J, Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7(1). van Lier D, Kox M, Santos K, van der Hoeven H, Pillay J, Pickkers P. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7(1).
37.
go back to reference Lundström A, Ziegler L, Havervall S, Rudberg AS, Von Meijenfeldt F, Lisman T, et al. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers. J Med Virol. 2021;93(10):5908–16.PubMedPubMedCentralCrossRef Lundström A, Ziegler L, Havervall S, Rudberg AS, Von Meijenfeldt F, Lisman T, et al. Soluble angiotensin-converting enzyme 2 is transiently elevated in COVID‐19 and correlates with specific inflammatory and endothelial markers. J Med Virol. 2021;93(10):5908–16.PubMedPubMedCentralCrossRef
38.
go back to reference Shevchuk O, Pak A, Palii S, Ivankiv Y, Kozak K, Korda M, et al. Blood ACE2 protein level correlates with COVID-19 severity. Int J Mol Sci. 2023;24(18):13957.PubMedPubMedCentralCrossRef Shevchuk O, Pak A, Palii S, Ivankiv Y, Kozak K, Korda M, et al. Blood ACE2 protein level correlates with COVID-19 severity. Int J Mol Sci. 2023;24(18):13957.PubMedPubMedCentralCrossRef
39.
go back to reference Wissing SI, Obeid R, Rädle-Hurst T, Rohrer T, Herr C, Schöpe J, et al. Concentrations of soluble angiotensin converting enzyme 2 (sACE2) in children and adults with and without COVID-19. J Clin Med. 2022;11(22):6799.PubMedPubMedCentralCrossRef Wissing SI, Obeid R, Rädle-Hurst T, Rohrer T, Herr C, Schöpe J, et al. Concentrations of soluble angiotensin converting enzyme 2 (sACE2) in children and adults with and without COVID-19. J Clin Med. 2022;11(22):6799.PubMedPubMedCentralCrossRef
40.
go back to reference Gheware A, Ray A, Rana D, Bajpai P, Nambirajan A, Arulselvi S, et al. ACE2 protein expression in lung tissues of severe COVID-19 infection. Sci Rep. 2022;12(1):4058.PubMedPubMedCentralCrossRef Gheware A, Ray A, Rana D, Bajpai P, Nambirajan A, Arulselvi S, et al. ACE2 protein expression in lung tissues of severe COVID-19 infection. Sci Rep. 2022;12(1):4058.PubMedPubMedCentralCrossRef
41.
go back to reference Kragstrup TW, Singh HS, Grundberg I, Nielsen AL-L, Rivellese F, Mehta A, et al. Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. PLoS ONE. 2021;16(6):e0252799.PubMedPubMedCentralCrossRef Kragstrup TW, Singh HS, Grundberg I, Nielsen AL-L, Rivellese F, Mehta A, et al. Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients. PLoS ONE. 2021;16(6):e0252799.PubMedPubMedCentralCrossRef
42.
43.
go back to reference Bani Hani A, Abu Tarboush N, Bani Ali M, Alabhoul F, Alansari F, Abuhani A, et al. Serum ACE2 level is Associated with severe SARS-CoV-2 infection: a cross-sectional observational study. Biomark Insights. 2022;17:11772719221125123.PubMedPubMedCentralCrossRef Bani Hani A, Abu Tarboush N, Bani Ali M, Alabhoul F, Alansari F, Abuhani A, et al. Serum ACE2 level is Associated with severe SARS-CoV-2 infection: a cross-sectional observational study. Biomark Insights. 2022;17:11772719221125123.PubMedPubMedCentralCrossRef
44.
go back to reference Robertson J, Nellgård B, Hultén LM, Nilsson S, Dalla K, Börjesson M, et al. Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls. Front Med. 2022;9:1058120.CrossRef Robertson J, Nellgård B, Hultén LM, Nilsson S, Dalla K, Börjesson M, et al. Sex difference in circulating soluble form of ACE2 protein in moderate and severe COVID-19 and healthy controls. Front Med. 2022;9:1058120.CrossRef
45.
go back to reference Triana S, Metz-Zumaran C, Ramirez C, Kee C, Doldan P, Shahraz M, et al. Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut. Mol Syst Biol. 2021;17(4):e10232.PubMedPubMedCentralCrossRef Triana S, Metz-Zumaran C, Ramirez C, Kee C, Doldan P, Shahraz M, et al. Single‐cell analyses reveal SARS‐CoV‐2 interference with intrinsic immune response in the human gut. Mol Syst Biol. 2021;17(4):e10232.PubMedPubMedCentralCrossRef
46.
47.
go back to reference Díaz-Troyano N, Gabriel-Medina P, Weber S, Klammer M, Barquín-DelPino R, Castillo-Ribelles L, et al. Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2. Diagnostics. 2022;12(4):886.PubMedPubMedCentralCrossRef Díaz-Troyano N, Gabriel-Medina P, Weber S, Klammer M, Barquín-DelPino R, Castillo-Ribelles L, et al. Soluble angiotensin-converting enzyme 2 as a prognostic biomarker for disease progression in patients infected with SARS-CoV-2. Diagnostics. 2022;12(4):886.PubMedPubMedCentralCrossRef
48.
go back to reference Maza MDC, Úbeda M, Delgado P, Horndler L, Llamas MA, van Santen HM, et al. ACE2 serum levels as Predictor of Infectability and Outcome in COVID-19. Front Immunol. 2022;13:836516.PubMedPubMedCentralCrossRef Maza MDC, Úbeda M, Delgado P, Horndler L, Llamas MA, van Santen HM, et al. ACE2 serum levels as Predictor of Infectability and Outcome in COVID-19. Front Immunol. 2022;13:836516.PubMedPubMedCentralCrossRef
49.
go back to reference Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, et al. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020;396(10256):968–76.PubMedPubMedCentralCrossRef Narula S, Yusuf S, Chong M, Ramasundarahettige C, Rangarajan S, Bangdiwala SI, et al. Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. Lancet. 2020;396(10256):968–76.PubMedPubMedCentralCrossRef
50.
go back to reference Giannella A, Riccetti S, Sinigaglia A, Piubelli C, Razzaboni E, Di Battista P, et al. Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients. Front Immunol. 2022;13:968991.PubMedPubMedCentralCrossRef Giannella A, Riccetti S, Sinigaglia A, Piubelli C, Razzaboni E, Di Battista P, et al. Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients. Front Immunol. 2022;13:968991.PubMedPubMedCentralCrossRef
Metadata
Title
Evaluation of angiotensin converting enzyme 2 (ACE2), angiotensin II (Ang II), miR-141-3p, and miR-421 levels in SARS-CoV-2 patients: a case-control study
Authors
Ehsan Kakavandi
Kaveh Sadeghi
Mohammad Shayestehpour
Hossein Mirhendi
Abbas Rahimi Foroushani
Talat Mokhtari-Azad
Nazanin Zahra Shafiei Jandaghi
Jila Yavarian
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2024
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-024-09310-3

Other articles of this Issue 1/2024

BMC Infectious Diseases 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.